|Application ||WB, IF, E|
|Other Accession||EAW80952, 119601358|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||Predicted: 280 kDa; Observed: 260 kDa|
|Application Notes||SPG15 antibody can be used for detection of SPG15 by Western blot at 1 - 2 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||ZFYVE26; Multiple isoforms of SPG15 are known to exist.|
|Reconstitution & Storage||SPG15 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||SPG15 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Phosphatidylinositol 3-phosphate-binding protein required for the abcission step in cytokinesis: recruited to the midbody during cytokinesis and acts as a regulator of abcission. May also be required for efficient homologous recombination DNA double-strand break repair.|
|Cellular Location||Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Midbody. Note=Localizes to the centrosome during all stages of the cell cycle. Recruited to the midbody during cytokinesis by KIF13A|
|Tissue Location||Strongest expression in the adrenal gland, bone marrow, adult brain, fetal brain, lung, placenta, prostate, skeletal muscle, testis, thymus, and retina. Intermediate levels are detected in other structures, including the spinal cord|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SPG15 Antibody: Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders. Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia in which mental retardation and muscle stiffness at onset are followed by slowly progressive paraparesis and cognitive deterioration. SPG15 is the second gene known to be responsible for ARHSP-TCC in the Italian population. Mutations in this gene are associated with autosomal recessive spastic paraplegia-15. SPG15 encodes a protein containing a FYVE zinc finger binding domain which is thought to target these proteins to membrane lipids through interaction with phospholipids in the membrane. SPG15 mRNA is widely distributed in human tissues, as well as in rat embryos, suggesting a possible role for this protein during embryonic development. SPG15 co-localizes partially with endoplasmic reticulum and endosome markers, suggesting a role in intracellular trafficking.
Hughes CA, Byrne PC, Webb S, et al. SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q. Neurology 2001; 56:1230-3.
Denora PS, Muglia M, Casali C, et al. Spastic paraplegia with thinning of the corpus callosum and white matter abnormalities: further mutations and relative frequency in ZFYVE26/SPG15 in the Italian population. J. Neurol. Sci. 2009; 277:22-5.
Hanein S, Martin E, Boukhris A, et al. Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am. J. Hum. Genet. 2008; 82:992-1002.
Boukhris A, Feki I, Denis E, et al. Spastic paraplegia 15: linkage and clinical description of three Tunisian families. Mov. Disord. 2008; 23:429-33.
If you have any additional inquiries please email technical services at email@example.com.